NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Talazoparib (TALZENNA) received a category 1 recommendation from the National Comprehensive Cancer Network® (NCCN®)2
Category 1 definition: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Talazoparib is a preferred treatment option for recurrent or stage IV breast cancer patients with a germline BRCA1/2 mutation*
*Assess for germline BRCA1/2 mutations in all patients with recurrent or metastatic breast cancer to identify candidates for PARP inhibitor therapy.
The NCCN Guidelines above fall outside the talazoparib (TALZENNA) US Prescribing Information
 
TALZENNA Indication1
TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)‑mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA.
The appropriate use of TALZENNA should be based on risk/benefit assessment by the practitioner for an individual patient.
REFERENCES
  1. TALZENNA [prescribing information]. New York, NY: Pfizer Inc.; 2020.
  2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.4.2020. © 2020 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed June 8, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  3. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753-763.